Effect of Centella Asiatica on Vascular Endothelial Function in Older Adults
| Registry | NCT06472791 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: quadruple, other |
| Enrollment | 23 (Actual) |
| Sponsor | National University of Natural Medicine (Other) |
| Conditions | Endothelial Dysfunction |
| Interventions | Centella Asiatica, Placebo Comparator (Dietary supplement) |
| Dates | start 2025-02-01, primary completion 2025-12-31, completion 2025-12-31, first posted 2024-06-25, last updated 2026-07-01 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
All trials for Endothelial Dysfunction All trials of Centella Asiatica All trials of Placebo Comparator
The purpose of this study is to determine the effects of a dietary supplement containing centella asiatica on on vascular endothelial function in older adults.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Centlla Asiatica | Experimental | Dietary Supplement: Centella Asiatica | 250 mg/day (1 capsules) for week 1. 500 mg/day (2 capsules) for week 2. 750 mg/day (3 capsules) for week 3. 1000 mg/ day (4 capsules) for week 4. |
| Placebo | Placebo comparator | Dietary Supplement: Placebo Comparator | Matched number of capsules per week. Capsules will contain microcrystalline cellulose. |
Sex: All, ages: 50 Years to 85 Years, accepts healthy volunteers
Inclusion Criteria: ● Age 50 through 85, male or female * Sufficient proficiency in English to understand study purpose and directions * Willing and able to give informed consent * Able to follow protocol and attend visits Exclusion Criteria: * History of myocardial infarction, known coronary or carotid disease, or heart failure * History of stroke, Parkinson's disease, dementia, or other major CNS disorders * History of hepatic disease (e.g. hepatitis, cirrhosis) * Recent/recurring history of severe life-threatening medical conditions (e.g. cancer, except non-melanoma skin cancers) * Active major infectious disease (e.g. pneumonia) * Heavy alcohol use (15 drinks or more per week for men or 8 drinks or more per week for women) or substance use disorder * Current use of any medication typically used to treat hypertension or lower blood pressure (e.g. beta-blockers, ACE inhibitors) * Current use of any medication typically used to prevent the coagulation of blood (e.g. warfarin (Coumadin)) * Chronic NSAID use (>3 times a week for more than 3 months) * Current use of any medication or supplement typically used as a sedative (e.g. zolpidem (Ambien), benzodiazepines (Valium, Xanax), valerian root) * Dietary supplements for improving nitric-oxide synthesis (e.g. L-arginine, L-citrulline) * Current use of any medication typically used to control hypoglycemia (e.g. biguanides (Metformin)) * Current use of any medication typically used for erectile dysfunction (e.g. sildenafil (Viagra), tadalafil (Cialis)) * Pregnant, nursing, or planning a pregnancy within the next 6 weeks * Open skin rashes and sores that may interfere with the placement of sensors
| Facility | City | Country | Status |
|---|---|---|---|
| Helfgott Research Institute | Portland, Oregon | United States |